Podcasts about Leach

Tom talks with Jack Givens, Justin Rowland, and more.

Dick Gabriel fills in for Tom to talk with Christi Thomas and Darrell Bird.

Life, Culture and Current Events from a Biblical Perspective with Neil Johnson.Your support sends the gospel to every corner of Australia through broadcast, online and print media: https://vision.org.au/donateSee omnystudio.com/listener for privacy information.

On this Salcedo Storm Podcast:Matt Thorsen is running for House District 67. He represents the grassroots, small-business, family-focused conservative and has lived the challenges everyday Texans face like running a small business, raising a family, and working in the community to build opportunity.

Tom talks with Keith Farmer, Larry Vaught, Brandon Ramsey.

Tom talks with Will Stein, Ben Roberts, and Dick Gabriel.

Tom talks with Jack Givens, Maggie Davis, and Justin Rowland.

Dick Gabriel talks with Jeff Drummond and Lee K. Howard.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Modern healthcare treats symptoms, but what if illness begins at a deeper level most systems ignore? Naturopath Nicholas Leach joins InnerVerse to explore terrain theory, trauma, consciousness, and the true foundations of healing. Our conversation shines light on the root causes of health issues, the limitations of germ theory, and the importance of terrain and worldview healing. Discover how natural laws, electromagnetic fields, and emotional health influence overall well-being.Hour two carries us towards exploring health, herbs, consciousness, and the interconnectedness of body, mind, and spirit, including practical approaches for resolving trauma, hypersensitivity. We also get into the teaching power of plants and healing abilities of sound.Get the Full Episode by joining InnerVerse Plus+ on Substack, Patreon, or Youtube. LINKSNicholas Leach: https://knowthyhealing.com/Video Episode: https://youtu.be/-nUaGwaNZKMBiofield Tuning with Chance: https://www.innerversepodcast.com/sound-healingTarot Readings with Chance: https://www.innerversepodcast.com/oracle-cardsThe Elementals Gathering: https://createmore.com.au/elementals/SUPPORTKyle Denton's Potent Plant Medicines – Tippecanoe Herbs (use coupon code 'innerverse'): https://www.tippecanoeherbs.comSupport InnerVerse by trying Melissa's Homepathic Remedies (use coupon code 'innerverse'): https://rmdycollective.com/chancegartonFlower Elixirs by LotusWei: https://www.lotuswei.com/innerverseLearn To Trade Like A Wizard: https://www.skool.com/tradingbusiness/about?ref=6043c01b48d04a20ba5e90e1dd83602d Hosted on Acast. See acast.com/privacy for more information.

Tom talks with Larry Vaught, Jon Hale, and Kendrick Haskins.

Tom talks with Darrel Bird and Mark Story.

Tom talks with Brandon Ramsey and Mike Decourcy.

Busy Show on Friday! Captain Robert Wells breaks down the US-Iran situation, followed by Mark Van Buren counting down the Top 10 Robert Duvall movies, then State Senator Vince Leach stopping by to give us a legislative update! Only on the Live the Dream Media Network!

Tom talks with Jenna Lifshen, Jack Givens, and Justin Rowland.

“We’re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,” Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company’s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyond. In this Vanguards of Health Care podcast episode, Leach joins BI analyst Matt Henriksson for an in-depth discussion on Dexcom’s transition to the G7 15 Day sensor, aimed to reduce the frequency of changing sensors, as well as clinical data efforts to expand reimbursement to diabetic patients not on insulin and updates on the next-generation G8. He also reflects on his 22-year journey at Dexcom, rising from an engineer on a 30-person team to CEO of an 11,000-employee company.See omnystudio.com/listener for privacy information.

We trace Camille's journey from childhood fear and college doubt to a practical, grace-filled approach to parenting. Identity in Christ, renewing the mind with Scripture, and simple practices transform shame, mom rage, and marriage strain into steady peace.• fear-led faith reshaped by Scripture• Peru breakthrough on Pharaoh and God's wrath• union with Christ and freedom from sin in Romans• Alaska hardship, loss, and identity crisis• naming shame as the engine of mom rage• four-step reset after yelling to break cycles• rooting worth in Christ, not performance• rewiring triggers with verses and visualization• releasing control, gossip, and bitterness• speaking life: “describe what you see”• anger as a signal, not a master• training kids with Scripture and respectful disagreement• building contentment and truth-telling identities

Tom talks with Jeff Piecoro, Kyle Tucker, and more.

Tom talks with Scott Howard, Larry Vaught, and Nick Mingione.

In this episode, I sit down with Michael Leach for a thoughtful conversation about fear, faith, and what it looks like to keep moving forward when clarity is hard to come by. We talk about his journey from growing up on the South Side of Chicago to working in the NFL and serving in the White House, but more importantly about how faith is formed through practice, resilience, and trust in uncertain seasons. We explore purpose and identity, calling versus assignment, burnout and boundaries, and why connection matters more than simply having the right words. This is an honest, grounded conversation about choosing faith over fear and learning how to live with courage and moral clarity in a complicated world.Michael Leach is a distinguished leader whose career spans the NFL, national politics, and the White House. Born on the South Side of Chicago, his journey has shaped him into one of today's most trusted and relatable voices on faith, leadership, and resilience. He began with the Chicago Bears, advanced to NFL Headquarters, helped lead and build the most diverse presidential campaign team in U.S. history, culminating in a historic victory, and later made history as the first-ever Chief Diversity & Inclusion Officer of the White House. Now Founder & CEO of BridgeTrust Partners, Leach helps leaders and organizations strengthen trust, purpose, and impact across industries.Michael's Book:Faith Over FearMichael's Recommendation:The One ThingConnect with Joshua: jjohnson@shiftingculturepodcast.comGo to www.shiftingculturepodcast.com to interact and donate. Every donation helps to produce more podcasts for you to enjoy.Follow on Facebook, Instagram, Twitter, Threads, Bluesky or YouTubeConsider Giving to the podcast and to the ministry that my wife and I do around the world. Just click on the support the show link belowGet Your Sidekick Support the show

Dick Gabriel talks with Darren Headrick, Jack Givens, and Justin Rowland.

Dick Gabriel talks with Jon Hale, Derek Terry, and more.

Tom talks with Larry Vaught, Keith Farmer, and Jeff Drummond.

Tom talks with Ben Roberts, Darren Headrick, and Kent Spencer.

“My past does not define me, but it does give purpose to the work I do today.”-JD Leach In this powerful episode of The Krista Escamilla Show, Krista sits down with JD Leach, author, actor, father, and juvenile justice reform advocate, to share his deeply personal journey through the Texas juvenile justice system and beyond. JD is the author of the memoir Behind Closed Eyes: The Echoes From Texas Juvenile Prison, where he courageously details his survival, rehabilitation, and the realities faced by young people inside the system. Having spent many years in the oilfields of Midland, JD's story is one rooted in West Texas, resilience, and redemption. Today, JD lives in Granbury, Texas, where he continues to advocate for reform, raise awareness, and share his story to help protect and empower vulnerable youth. He has also appeared in the film Lioness and recently filmed Stan the Man, using storytelling both on and off screen to spark conversation and change.

Tom talks with Chris Dotch and Mike DeCourcy.

Tom talks with Justin Rowland, Danny Neal, and Dick Gabriel.

Tom talks with Jeff Sheppard, Jack Givens, and Darrell Bird.

Tom talks with Larry Vaught, Maggie Davis, and Kendrick Haskins.

This week on Oil & Whiskey, Andy Leach and the Cal Automotive Creations crew roll through in person, and they didn't come alone. Andy's back in the studio with Matt, Rick, and even Andy's wife (aka the real chaperone / brains of the operation). We catch up on what they've been up to since the last time Andy was on. Including a major Slonaker win, how they took a rare “quiet year” to focus on the shop and actually be home for the kids' stuff, and what they changed internally to keep everything moving. Then it turns into classic O&W shop talk: big projects, what it's like when a client trusts the team and lets them push it, and the behind-the-scenes excitement around a seriously next-level Roadster Shop chassis project . It's a long-form hang with a killer crew

Tom talks with Brandon Ramsey, Noah Cierzan, and Darren Headrick.

Tom talks with Mike DeCourcy, Mark Story, and more.

Tom talks with Jack Givens and Justin Rowland.

Dick Gabriel talks with Larry Vaught, Lee K. Howard, and Chris Shoals.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: UK looks at starting universal T1D screening, Dexcom's CEO mentions a new product, bariatric sugery vs GLP medications, FDA approves update to prescribing info for inhaled insulin, miscroplastic and diabetes link studied, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: (Stacey Track) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. We are less than one month from our first MNO of 2026. Please join us in Silver Spring MD Feb 20 and 21. It's going to be amazing. We're going to Nashville next March 6-7 and we're going to have a great event a Club 1921 we just added on Thursday March 5th for health care providers and patient leaders. All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX   All UK children could be offered screening for type 1 diabetes using a simple finger-prick blood test, say researchers who have been running a large study. This is the ELSA study - Early Surveillance for Autoimmune diabetes, a first of its kind UK study. They tested blood samples from 17,931 children aged 3-13 for autoantibodies, markers of type 1 diabetes that can appear years before symptoms. Families of children found to have early-stage type 1 diabetes received tailored education and ongoing support to prepare for the eventual onset of type 1 diabetes symptoms and to ensure insulin therapy can begin promptly when needed, reducing the chances of needing emergency treatment. Those with one autoantibody also received ongoing support and monitoring.   Some families were also offered teplizumab, the first ever immunotherapy for type 1 diabetes, which can delay the need for insulin by around three years in people with early-stage type 1 diabetes. The second phase has launched and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children (2-3 years) and older teenagers (14-17 years). The research team aims to recruit 30,000 additional children across these new age groups. ELSA 2 will assess how screening can be scaled across the NHS and evaluate its cost-effectiveness. https://www.birmingham.ac.uk/news/2026/childhood-type-1-diabetes-screening-is-effective-and-could-prevent-thousands-of-emergency-diagnoses XX At the J.P. Morgan Healthcare Conference Dexcom CEO Jake Leach says they're going to launch a new product outside the US. I'll link up that interview, The full quote: "When you look at the outside the U.S., there are a lot of structures that are tiered. Patients have access to different types of products, so we've got a new one that we want to introduce that will add flexibility there. It's based on the G7 platform, just like Dexcom ONE+, but it has a unique experience that's tailored for a subset of users that, today, don't have access to Dexcom." Your guess is as good as mine, but sounds more like a pricing or ordering issue than a new bit of hardware or software. Dexcom will also bring Stelo to some international markets this year. And plans a new mobile app experience for the wearable biosensor meant for people who don't dose insulin. Leach also says G8 will be much smaller and with more capability. but is a few years away. https://www.drugdeliverybusiness.com/dexcom-ceo-jake-leach-2026-roadmap-jpm/ XX A new international consensus statement provides guidance for the use of diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD).   Organized by the diaTribe Foundation, the document was based on evidence where available, as well as opinion from an international group of experts in endocrinology, diabetes technology, and obstetrics & gynecology, among others.   This is the first set of recommendations specifically addressing the use of diabetes technology in pregnancy – and we'll link it up. https://www.medscape.com/viewarticle/new-consensus-statement-addresses-diabetes-tech-pregnancy-2026a100020d XX Bariatric surgery beats GLP-1s for type 2 diabetes across income levels. This study was published this month, looking at nearly 300 patients are 4 medical centers. Success here is measured by lower blood glucose levels, higher weight loss (28% vs. 10%), less use of diabetes medications, remission of diabetes to the point of no longer needing to inject insulin, and reduced risk factors for cardiovascular disease.     Bariatric surgery was better than medical therapy across all social backgrounds, they found, and not just in areas of higher deprivation. The ancillary study was smaller, and some of the participants randomized in earlier stages crossed over from medical to surgical treatment, and the reverse. The authors acknowledged and accounted for these limitations, along with the rapid development of more powerful obesity drugs not fully captured in the study. This was a long term study – more than 12 years – and by the end of the study more people were choosing GLP1 medications. One dividing line: If someone hopes to lose 100 pounds, that's more likely with surgery than with medications.  "Ultimately, we need large, long-term, well-designed studies to clarify the best strategy for a given patient." https://www.statnews.com/2026/01/19/diabetes-study-bariatric-surgery-better-than-glp-1s/ XX Researchers at the University of California, Riverside have reported for the first time that a father's exposure to microplastics (MPs) can lead to metabolic problems in his children, including diabetes. This is a mouse study, but it looks at a previously unrecognized way in which environmental pollution may influence the health of future generations. MPs are extremely small plastic fragments, measuring less than 5 millimeters, that form as consumer products and industrial materials break down. Metabolic disorders describe a group of conditions that include elevated blood pressure, high blood sugar, and excess body fat, all of which raise the risk of heart disease and diabetes. The team found that female offspring of male mice exposed to MPs were far more prone to metabolic disorders than offspring of unexposed fathers, even though all offspring received the same high fat diet.     The research team hopes the findings will guide future investigation into how MPs and even smaller nanoplastics affect human development.   https://scitechdaily.com/microplastics-can-rewire-sperm-triggering-diabetes-in-the-next-generation/ XX The FDA has finalized four new recalls for certain lots of Abbott's FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to ongoing safety concerns. We told you about this in November when Abbott says some of its continuous glucose monitoring (CGM) sensors were providing incorrect low glucose warnings. Internal testing identified the issue—carbon building up in the sensors during the manufacturing process—and determined that approximately 3 million CGM sensors were affected. The sensors were distributed in the United States, Canada and several European countries.  When Abbott shared that announcement, the FDA was still reviewing the situation. No recalls had yet been finalized. Now, however, the agency has announced four new Class I recalls.   https://cardiovascularbusiness.com/topics/clinical/heart-health/fda-confirms-recalls-abbott-cgm-sensors-new-lawsuit-alleges-company-concealed-information XX   Insulet brings back it's U.S. Pod recycling program, now making it available to all U.S. customers. The Pod recycling program, offered at no cost to customers, enables users to request a recycling kit online. This allows them to return their used Omnipods. Insulet then decontaminates the returned Pods before transporting them to a company specializing in recycling for electronics and medical products. Insulet began recycling pilot programs in Mass and California and are rolling it out nationwide. Insulet also has "Pod takeback" programs outside the U.S. in several international markets. These programs enable customers to request a takeback kit by contacting their local customer support team.   https://www.drugdeliverybusiness.com/insulet-expands-us-pod-recycling-program/ XX Up next a new resource for a population at three times the risk for diabetes, but without a lot of access to health information. I The first diabetes information website primarily in ASL has launched. The site includes GIFs and videos on diabetes management and an ASL glossary of diabetes-related terms. This is from University of Utah Health – Called Deaf Diabetes Can Together. Deaf and hard of hearing people are at three times higher risk for diabetes, but access to health information in ASL is limited. https://healthcare.utah.edu/newsroom/news/2026/01/first-diabetes-information-website-asl-launches XX Novo Nordisk ended all work on cell therapies, including a Type 1 diabetes program, in October – and now has found a buyer. Aspect has acquired rights to the assets and giving Novo an option to reengage for later-stage development and commercialization. Novo is helping bankroll Aspect's development of the assets, investing in the company and providing research funding. The arrangement gives Novo a chance to profit from the programs down the line. Novo is eligible for royalties and milestone payments on future product sales and, having handed the reins to Aspect for now, can expand its role in later-stage development and commercialization. The integration will involve the transfer of capabilities and expertise from Novo sites in Denmark and the U.S. to Aspect's Canadian operations. https://www.fiercebiotech.com/biotech/novo-nordisk-offloads-diabetes-assets-aspect-amid-cell-therapy-retreat XX XX Lucas Escobar has carved a role by proving that healthcare marketing can be culturally resonant, commercially powerful and deeply human. As director and head of U.S. consumer marketing at Insulet, he has redefined how the Omnipod tubeless insulin pump shows up in culture, transforming a medical device into a symbol of identity, inclusion and empowerment.   Under Escobar's leadership, Insulet launched three breakthrough initiatives: Dyasonic: Sound of Strength, a Marvel comic collaboration introducing a superhero who uses Omnipod; The Pod Drop, which turned the sound of a pod change into a celebratory music track; and Omnipod Mango x Pantone, medtech's first color partnership, honoring the vibrancy of the diabetes community. Each blended creativity with purpose while driving results, helping fuel Omnipod's consistent double-digit growth and its position as the most prescribed insulin pump in the U.S.   Living with type 1 diabetes himself, Escobar brings lived experience to his work, using storytelling not just to sell, but to make people feel seen.   Click here to return to the 2026 MM+M 40 Under 40 homepage.   From the January 01, 2026 Issue of MM+M - Medical Marketing and Media https://www.mmm-online.com/40-under-40/40-under-40-lucas-escobar-insulet/ -- FDA approves an update to the prescribing info for Afrezza inhaled insulin. This is a revision to the recommendations for the starting mealtime dosage when patients switch from shots or insulin pumps. This is aimed at healthcare providers - the updated labeling was supported by results from the INHALE-3 trial. The FDA is still considering approval of Afrezza for kids – a decision there expect by summer. https://www.globenewswire.com/news-release/2026/01/26/3225442/29517/en/MannKind-Announces-FDA-Approval-of-Updated-Afrezza-Label-Providing-Starting-Dose-Guidance-when-Switching-from-Multiple-Daily-Injections-MDI-or-Insulin-Pump-Mealtime-Therapy.html   -- UK researchers have developed a calculator to predict whether someone is at risk for type 1 diabetes. They're hoping this helps in screening and in preventing DKA at diagnosis. They used the TEDDY study to create this calculator, which right now is in beta form and only for kids and teens ages 8-18. The current beta form of the calculator asks users to answer questions about four factors necessary to estimate a child's risk of developing type 1 diabetes: age, family history, number of confirmed autoantibodies, and genetic risk score. The calculator has been given regulatory approval as a diagnostic in the U.K., and he's working with a company that's hoping to bring it to the U.S. in the next few months in the form of a home genetic test kit. https://www.healthcentral.com/news/type-1-diabetes/new-calculator-might-help-predict-type-1-diabetes-before-symptoms-appear

Tom talks with Kevin Ingram, Rob Dauster, and more.

Tom talks with CL Brown and Brandon Ramsey.

Tom talks with Jack Givens, Justin Rowland, and Carolina Makaukas.

Tom talks with Maggie Davis, Craig Way, and Darrel Bird.

Tom talks with Jon Hale, Larry Vaught, and Jenna Lifshen.

Terry Leach, Detective with the Fairfax County Police Department, took the stand in the murder trial of Brendan Banfield, the former IRS agent charged with four counts of aggravated murder in the deaths of his wife Christine Banfield and Joseph Ryan. Prosecutors allege Banfield and the family's au pair, Juliana Peres Magalhães, lured Ryan to their Herndon home through a fetish website and staged the killings as a home invasion.The defense argues digital forensics contradict the catfishing theory and that investigators who disagreed were reassigned. Banfield faces life without parole if convicted. The four-week trial continues in Fairfax County.#TrueCrimeToday #BrendanBanfield #AuPairAffair #MurderTrial #ChristineBanfield #JosephRyan #FairfaxCounty #JulianaMagalhaes #Justice #BreakingJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

Terry Leach, Detective with the Fairfax County Police Department, testified today in the Brendan Banfield murder trial. Banfield, a former IRS agent, is charged with four counts of aggravated murder in the February 2023 deaths of his wife Christine Banfield and Joseph Ryan at their Herndon, Virginia home.Prosecutors allege Banfield plotted the killings with the family's Brazilian au pair, Juliana Peres Magalhães, with whom he was having an affair. Magalhães has pleaded guilty to manslaughter and is expected to testify against Banfield. The defense maintains digital evidence does not support the state's catfishing theory.#BrendanBanfield #AuPairAffair #MurderTrial #TrueCrime #Testimony #ChristineBanfield #JosephRyan #FairfaxCounty #HiddenKillers #BreakingJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

See omnystudio.com/listener for privacy information.

John Anderson hosts a candid discussion with Gerard Holland, Freya Leach and Jossiah Langton about the immense social, economic and political pressures facing Gen Z. This generation is often described as disillusioned, anxious, and disengaged, yet beneath the headlines lies a complex story shaped by economic hardship, cultural uncertainty, and a loss of shared meaning. This is a conversation with three young Australians who are working to restore, not dismantle, the institutions that hold society together. From housing affordability and family formation to energy policy and political radicalisation, the discussion considers why confidence has eroded, and what must change if Australia is to recover a sense of shared purpose, responsibility and national continuity. Gerard Holland is the Chief Executive Officer of the Page Research Centre and has previously served as the Director of Outreach and Strategic Partnerships at the Alliance for Responsible Citizenship (ARC). Freya Leach is Co-Host of The Late Debate on Sky News Australia and is the Director of the Centre for Youth Policy at Menzies Research Centre. Jossiah Langton is the Operations and Engagement Manager for FORM Australia Ltd., a not-for-profit inspired by ARC, dedicated to elevating the quality of public leadership and discourse in Australia.